Breast Disease pp 239-246 | Cite as

Neoadjuvant Hormonal Therapy in Breast Cancer

  • Nil Molinas Mandel
  • Fatih Selcukbiricik


Estrogen receptor (ER)-positive and HER-2-negative breast cancers have various types and, consequently, different treatment modalities. In the treatment of locally advanced breast cancer, there are two options: chemotherapy or hormonal therapy. Chemotherapy can be toxic for postmenopausal elderly patients, and neoadjuvant hormonal therapy is an option for hormone receptor-positive locally advanced postmenopausal breast cancer. Such a treatment is also highly beneficial for patients with comorbidities. This treatment can be tamoxifen or steroidal or nonsteroidal aromatase inhibitors (AI). The best activities in clinical trials are observed with aromatase inhibitors. Neoadjuvant hormonotherapy is associated with good response rates as well as adequate downstaging of tumor size, and breast-conserving surgery may even become an option. The optimal duration of such a treatment should not be less than 4 months and may be as long as 8 months. Recently, new antihormonal therapies are being used for this purpose. There are no studies showing benefits of neoadjuvant endocrine therapy in premenopausal patients.


  1. 1.
    Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985;312:674–81.PubMedCrossRefGoogle Scholar
  2. 2.
    Silliman RA. What constitutes optimal care for older women with breast cancer? J Clin Oncol. 2003;21:3554–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Krainick-Strobel UE, Lichtenegger W, Wallwiener D, et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer. 2008;26(8):62. Scholar
  4. 4.
    Mustacchi G, Milani S, Pluchinotta A, et al. Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: the G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly. Anticancer Res. 1994;14:2197–200.PubMedGoogle Scholar
  5. 5.
    Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res. 2001;7:2620–35.PubMedGoogle Scholar
  6. 6.
    Goldhirsh A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2013;24(9):2206–23.CrossRefGoogle Scholar
  7. 7.
    Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995;13(3):547–52.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Charehbili A, Fontein DB, Kroep JR, et al. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review. Cancer Treat Rev. 2014;40(1):86–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Horobin JM, Preece PE, Dewar JA, Wood RA, Cuschieri A. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg. 1991;78(2):213–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Dixon JM, Love CD, Bellamy CO, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat. 2001;66(3):191–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer. 2002;38(17):2214–2.PubMedCrossRefGoogle Scholar
  12. 12.
    Mauriac L, Debled M, Durand M, et al. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol. 2002;13(2):293–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Tubiana-Hulin M, Becette V, Bieche I, et al. Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. Anticancer Res. 2007;27(4C):2689–96.PubMedGoogle Scholar
  14. 14.
    Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double blind multicenter study. Ann Oncol. 2001;2(11):1527–32.CrossRefGoogle Scholar
  15. 15.
    Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108–16.PubMedCrossRefGoogle Scholar
  16. 16.
    Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106(10):2095–103.PubMedCrossRefGoogle Scholar
  17. 17.
    Murray J, Young OE, Renshaw L, et al. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women. Breast Cancer Res Treat. 2009;114(3):495–501.PubMedCrossRefGoogle Scholar
  18. 18.
    Hille U, Soergel P, Langer F, Schippert C, Makowski L, Hillemanns P. Aromatase inhibitors as solely treatment in postmenopausal breast cancer patients. Breast J. 2012;18(2):145–50.PubMedCrossRefGoogle Scholar
  19. 19.
    Dixon JM, Renshaw L, Dixon J, Thomas J. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy. Breast Cancer Res Treat. 2011;130(3):871–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Olson JA Jr, Budd GT, Carey LA, et al. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg. 2009;208(5):906–14.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Gazet JC, Ford HT, Gray R, McConkey C, et al. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann Oncol. 2001;12(5):685–91.PubMedCrossRefGoogle Scholar
  22. 22.
    Torrisi R, Bagnardi V, Pruneri G, et al. Antitumour and biological effects ofletrozole and GnRH analogue as primary therapy in premenopausal womenwith ER and PgR positive locally advanced operable breast cancer. Br J Cancer. 2007;97(6):802–8.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Masuda N, Sagara Y, Kinoshita T, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012;13(4):345–52.PubMedCrossRefGoogle Scholar
  24. 24.
    Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2–3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype – ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–9.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110(2):244–54.PubMedCrossRefGoogle Scholar
  26. 26.
    Alba E, Calvo L, Albanell J, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012;23(12):3069–74.PubMedCrossRefGoogle Scholar
  27. 27.
    Colleoni M, Montagna E. Neoadjuvant therapy for ER-positive breast cancers. Ann Oncol. 2012;23(suppl 10):x243–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Polk A, Kolmos IL, Kümler I, Nielsen DL. Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence. ESMO Open. 2017;1(6):e000093.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Tamura K, Kodaira M, Shimizu C, Yonemori K, Yunokawa M, Shimomura A et al. Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer. Cancer Sci. 2018;3. Scholar
  30. 30. A study of neoadjuvant letrozole + GDC-0032 versus letrozole + placebo in post-menopausal women with breast cancer (LORELEI). NCT02273973. 2016. Accessed 15 Jan 2016.
  31. 31. A phase II randomized study evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in post-menopausal women with estrogen-receptor positive primary breast cancer. NCT02296801. 2016. Accessed 15 Jan 2016.
  32. 32.
    Ma CX, Gao F, Northfelt D, et al. A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+HER2−) breast cancer (BC). Presented at: San Antonio Breast Cancer Symposium; December 11, 2015; San Antonio, TX. Abstract S6-05.Google Scholar
  33. 33.
    Criscitiello C, Viale G, Curigliano G. Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting. Curr Opin Oncol. 2017;29(6):428–33.PubMedCrossRefGoogle Scholar
  34. 34.
    Palmieri C, Cleator S, Kilburn LS, et al. NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. Breast Cancer Res Treat. 2014;148(3):581–90.PubMedCrossRefGoogle Scholar
  35. 35.
    Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19(18):3808–16.PubMedCrossRefGoogle Scholar
  36. 36.
    Hojo T, Kinoshita T, Imoto S, et al. Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: a randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy. Breast. 2013;22(3):263–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Kuter I, Gee JMW, Hegg R, et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized phase II study. Breast Cancer Res Treat. 2012;133(1):237–46.PubMedCrossRefGoogle Scholar
  38. 38.
    Polychronis A, Sinnett HD, Hadjiminas D, et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol. 2005;6(6):383–91.PubMedCrossRefGoogle Scholar
  39. 39.
    Fasching PA, Jud SM, Hauschild M, et al. FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. BMC Cancer. 2014;14(1):66.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Mohammadianpanah M, Ashouri Y, Hoseini S, et al. The efficacy and safety of neoadjuvant chemotherapy +/− letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial. Breast Cancer Res Treat. 2012;132(3):853–61.PubMedCrossRefGoogle Scholar
  41. 41.
    Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477–86.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Goncalves R, DeSchryver K, Ma C, Tao Y, Hoog J, Cheang M, et al. Development of a Ki-67 based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. Breast Cancer Res Treat. 2017;165(2):355–64.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017;35(10):1061–9.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG (outside the USA) 2019

Authors and Affiliations

  • Nil Molinas Mandel
    • 1
  • Fatih Selcukbiricik
    • 1
  1. 1.Koc University Medical Faculty, Department of Medical OncologyIstanbulTurkey

Personalised recommendations